COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Adult Outpatients With SARS-CoV-2 Infection

NCT04666441 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

1149

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19

Interventions

DRUG: REGN10933+REGN10987 combination therapy
DRUG: Placebo

Sponsor

Regeneron Pharmaceuticals